Radiolabelled somatostatin peptides

Drug Profile

Radiolabelled somatostatin peptides

Alternative Names: MK 678-derived somatostatin peptides; Seglitide analogue; Somatoscan; Somatostatin peptides; Somatostatin Therapy

Latest Information Update: 13 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DRAXIS Specialty Pharmaceuticals
  • Class Antineoplastics; Cyclic peptides; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 13 Sep 2007 No development reported - Preclinical for Cancer diagnosis in Canada (unspecified route)
  • 13 Sep 2007 No development reported - Preclinical for Cancer in Canada (unspecified route)
  • 10 Feb 2005 Preclinical trials in Cancer diagnosis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top